Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

Cytokinetics, Incorporated (Nasdaq: CYTK) will provide an update on the company's cardiac myosin modulation programs and ...

A recent study found that tirzepatide, the active ingredient in Zepbound and Mounjaro, could reduce the risk of ...

can reduce heart failure-related symptoms and improve physical limitations and exercise function in people with obesity-related HFpEF, with or without type 2 diabetes. Also Read: Ozempic Maker ...

Treatment of HFpEF should take the whole person into account, not just your heart. A sound treatment plan usually starts with controlling blood pressure and relieving fluid overload that can cause ...

Introduction: Heart failure with preserved ejection fraction (HFpEF) is a heterogenous clinical syndrome that accounts for nearly half of all heart failure cases world-wide. The pathophysiological ...

This update in the European Union (EU) reflects new data indicating the product’s ability, along with a standard of care, to alleviate symptoms related to heart failure and enhance physical function ...

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...

The label update incorporates data showing that Wegovy ®, when added to standard of care, can reduce heart failure-related symptoms and improve physical limitations and exercise function in people ...

Background: Transition from fatty acid oxidation to glycolysis is linked to oncometabolism and cardiac hypertrophy. We hypothesize that such a metabolic shift is pivotal in driving HFpEF in 3 murine ...